Harbin Partners LP

China Health

Harbin Partners is an equity stake in Harbin Pharmaceuticals, a leading Chinese pharmaceutical franchise and one of the most established consumer brands in China. It is involved in the manufacturing and distribution of prescription and OTC drugs, traditional Chinese medicine products, medical equipment, drug manufacturing machinery and chemical raw materials and products.

This investment was made under a previous strategy. We disclose information on all our current investments, but narrative information on our pre-2012 investments, when we introduced a new strategy, may be limited.

We are invested in Harbin Partners LP through CITIC Capital China, which is managed by CITIC Capital. For further information on the fund, the fund manager, and the expected impact of the fund’s investment, click here.

Key facts

Status:
Active
Region

Since 2012, we’ve only invested in Africa and South Asia. Investments outside these regions are from our pre-2012 portfolio.

:
Rest of the World
Countries:
China
Sector

We have seven priority sectors. However, we continue to invest outside these sectors, largely in the most challenging regions, as new investment supporting any sector helps to underpin the private sector, and create jobs and livelihoods for people.

:
Health
Investment type

We provide capital in three broad ways: direct equity, debt, and intermediated equity (principally through investment funds).

:
Intermediated investment
Fund:
CITIC Capital China
Fund Manager:
CITIC Capital
Start date

For direct investments, this is the date CDC committed capital to the business or project.

For funds, this is the date that CDC committed capital to the fund.

For underlying fund investments, this is the date that the fund invested capital into the business.e

:
August 2005
Domicile

This is the investee company’s place of incorporation; or a fund’s jurisdiction.

:
China